Sentences with phrase «cell based therapies for»

NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world - leading consortium that can develop stem cell based therapies for Parkinson's disease and Huntington's disease toward clinical application... Read more»

NeuroStemcell is formed to create a world - leading consortium that can take stem cell based therapies for Parkinson's disease (PD) and Huntington's disease (HD) to the clinic.

Not exact matches

• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.

Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline.

In a rare appearance Dr. Chandan Sen, Director, OSU Center for Regenerative Medicine & Cell - Based Therapies will explain how this breakthrough came about and how the technology is leading to other medical discoveries and how the principle can be used to generate any tissue out of skin or fat which is abundant in human body.

He hopes Medicine by Design's collaboration with Rotman will help cultivate a new generation of bioscience entrepreneurs who will strengthen Toronto as a global hub for stem cell - based therapies and help Canada realize its full potential in the field.

Overcoming the immense logistical challenges involved with withdrawing, shipping, modifying, returning, then reinfusing cells for every patient treated paints a scary question mark on the future of cell - based cancer therapies.

However, centres in the US and Europe are already banking testicular tissue for boys in the hope that new stem - cell - based therapies will become available.

Advanced Cell Technology, based in Santa Monica California, is developing embryonic stem cell therapies for macular degeneration and other conditions using cells obtained non-destructively from an early embryo called a blastocCell Technology, based in Santa Monica California, is developing embryonic stem cell therapies for macular degeneration and other conditions using cells obtained non-destructively from an early embryo called a blastoccell therapies for macular degeneration and other conditions using cells obtained non-destructively from an early embryo called a blastocyst.

Even if positive results emerge from these trials, ACT will still face major challenges in getting an ES - cell - based therapy approved for wider use.

There are no current treatments for HD, although Thompson's ongoing work with stem cell - based therapies are showing promise.

An extended transplant window could make time for drug or stem - cell based treatments — even gene therapy.

The immediate payoff was a commercialization deal in age - related macular degeneration in which Pfizer became the first big pharma company to make a move into the use of embryonic stem cells as the basis for a tissue regeneration therapy.

«There is an unmet need to develop new therapies based on R - CHOP to try to increase the cure rate for diffuse large B - cell lymphoma,» says Patrick Johnston, M.D., Ph.D., a hematologist at Mayo Clinic and lead author.

This new blend can cut the cost for health providers and makes progress towards effective cell - based therapy for cartilage repair a step closer.»

«Cartilage cells (or chondrocytes) isolated and expanded from cartilage tissue have great potential as a cell - based therapy for patients with, for example, traumatic cartilage defects,» says Juha Piltti, doctoral student at the Department of Integrative Medical Biology.

They may also have implications for current clinical trials testing stem - cell - based therapies for diabetes.

Based on a report published on August 20, 2015 in Nature Communications, it has been established that certain nutrients support CML stem cell activity in vivo, thus pointing towards a potential therapeutic target for CML therapy.

They do not yet form the basis for a therapy, researchers said, because methods must still be perfected to get them more selectively into the cancer cells.

Because the precise activation of Hox genes is essential for a cell's fate, «the research should prove extremely useful in developing novel embryonic stem cell - based therapies, Mazzoni adds.

She is currently at Rockefeller University, where she is studying the interactions between immune cells and stem cells in an effort to develop stem cell - based therapies for inflammatory disorders.

Boston Children's Hospital has offered non-exclusive licenses to for - profit entities on a patent developed by Orkin's laboratory regarding BCL11A, a genetic switch regulating hemoglobin production that is expected to form the basis of clinical trials for gene therapy and gene editing for sickle cell disease and thalassemia.

The researchers, who are based at the Academy of Scientific & Innovative Research, located at the CSIR - Indian Institute of Chemical Technology, Hyderabad, India, hope that the technique can enhance regenerative therapy for conditions like chronic wounds, where harsh inflammation in the wound can kill the cells used in regenerative stem cell treatments.

She is currently at Rockefeller University, where she is studying the interactions between immune cells and stem cells in an effort to develop stem cell — based therapies for inflammatory disorders.

Three of the original 10 centers have basically been extended for a second decade: the Center for Metropolitan Studies, the Center for Cell - Based Therapy, and the Center for the Study of Violence.

The Center for Cell - Based Therapy at the University of São Paulo was one of three centers to receive funding in both the first and second rounds of the RIDC program.

The technique «potentially provides ways to create model systems for studying the genetic basis of diabetes, or to discover novel therapies to enhance existing β cells,» Ferrer says.

The complete list is: the Food Research Center; the Center for Research, Teaching, and Innovation in Glass; the Center for Research and Development of Functional Materials; the Brazilian Research Institute for Neuroscience and Neurotechnology; the Center for Research on Inflammatory Diseases; the Center for Research and Innovation in Biodiversity and Drug Discovery; the Center for Research on Toxins, Immune Response, and Cell Signaling; the Research, Innovation and Dissemination Center for Neuromathematics; the Center for Research in Mathematical Sciences Applied to Industry; the Obesity and Co-Morbidities Research Center; the Center for Cell - Based Therapy; the Center for Metropolitan Studies; the Human Genome and Stem - Cell Research Center; the Center for Computational Science and Engineering; the Center for Research on Redox Processes in Biomedicine; the Center for the Study of Violence; and the Optics and Photonics Research Center.

Ultimately, however, these insights could broaden the repertoire of tissues that can be generated from stem cells, with significant implications for regenerative medicine and stem cell - based therapy.

The moves also include # 50 million ($ 78 million) for a London - based «cell therapy technology and innovation center,» and # 60 million ($ 93 million) to develop the secure system that would allow researchers access to anonymized patient data from the National Health Service (NHS).

After preclinical studies, a gene therapy trial for SCID - X1 was initiated, based on the use of complementary DNA containing a defective γc Moloney retrovirus — derived vector and ex vivo infection of CD34 + cells.

NRG Oncology researchers recently developed and validated a nomogram that can predict 2 - year and 5 - year overall survival (OS) and progression - free survival (PFS) for patients with local - regionally advanced oropharyngeal squamous cell carcinoma (OPSCC) treated primarily with radiation - based therapy.

He hopes that Cas9 - based therapies for T cell - related disorders, which include autoimmune diseases as well as immunodeficiencies such as «bubble boy disease,» will enter the clinic in the future.

That's the question raised by some perplexing new studies, providing another complication for researchers who are trying to develop advanced therapies based on neurons grown from stem cells.

The results, published in the current issue of Human Molecular Genetics, open the door for pursuing gene editing in nonhuman primates as models for new therapies, including pharmacological, gene - and stem cell - based therapies, said Keith Latham, MSU animal science professor and lead author of the study.

Ultimately, this knowledge will be useful for understanding the very early events in human development, which are reflected in the naïve and primed stem cell states, and could also lead to improved methods to reprogram human cells for stem cell - based therapies.

This is our dream for personalized cancer therapy, so we're not just guessing any more about which drugs will work but can choose drug targets based on what's driving that patient's cancer,» said Josh Stuart, the Baskin professor of biomolecular engineering at UC Santa Cruz, director of cancer and stem cell genomics at the UCSC Genomics Institute, and a senior corresponding author of the paper.

«Stem - cell - based therapy promising for treatment of breast cancer metastases in the brain.»

«Stem cell - based therapy for targeting skin - to - brain cancer: Stem cells loaded with oncolytic viruses show promising results in preclinical models for targeting skin cancer metastases in the brain.»

The advent of molecular cloning, DNA sequencing and the many tools of molecular genetics and cell biology has given us sufficient knowledge of the basis for disease and the genes to target, but what has limited the application of gene therapy has been efficient gene delivery systems.

These in turn can be used for disease modeling and drug discovery, but hopefully one day also for cell - based therapy of the many devastating diseases such as Alzheimer and Parkinson's Disease.

A physician with a longstanding interest in gene therapy, Dr. High was formerly a Professor at the Perelman School of Medicine of the University of Pennsylvania, an Investigator of the Howard Hughes Medical Institute, and the Founding Director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, a Center focused on developing novel cell and gene - based therapies for genetic disease.

Although we agree that greater investments are needed in the clinical development of these therapies, we disagree with the authors» suggestion that, relative to embryonic stem cells, adult stem cells provide a superior vehicle for cell - based therapies because they lack tumorigenic activity, can be prepared by methods approved by the Food and Drug Administration (FDA), and have been free of ethical controversy.

Cell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etCell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etc.).

CCTD is also planning stem cell - based research for diabetic eye disease, for which a variety of stem cell - based therapies have been evaluated in clinical trials.

It is also funding research aimed at a stem cell - based therapy for Parkinson's disease that is expected to lead to a clinical trial.

This should also enable commercialization of medical devices, reagents, and other products required for cell therapies through the development and dissemination of innovative methods and procedures for regenerative medicine based products.

Caribou recently cofounded Intellia Therapeutics for the development of human gene and cell therapies based on their proprietary CRISPR - Cas9 technology platform.

Thus, MGE, or MGE - like, precursors provide a great opportunity for cell - based therapy in animal models of neurological disorders linked to impaired inhibitory function.

A full realisation of the medical potential of stem cells for human health will likely depend on a reinforcement of, and development of a whole continuum of studies ranging from those in vivo using model organisms, to cell - based therapies in the clinic.